Yixuan Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Yixuan Chen has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Jianmin Niu
Department of Obstetrics, Shenzhen Maternity & Child Healthcare Hospital, Guangdong, China
2 shared publications - Aiqi Yin
Department of Obstetrics Shenzhen Maternity and Child Healthcare Hospital Shenzhen Guangdong China
1 shared publication - Cuiping Zeng
Department of Obstetrics and Gynecology, the Eighth Affiliated Hospital Sun Yat‐sen University Shenzhen Guangdong China
1 shared publication Hangkuan Liu
Department of Cardiology Tianjin Medical University General Hospital Tianjin China
1 shared publicationHuafan Zhang
Department of Obstetrics Shenzhen Maternity and Child Healthcare Hospital Shenzhen Guangdong China
1 shared publicationJianhua Yin
BGI research, Shenzhen, China
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 5 January 2024
- Published by Springer Nature in Communications Biology
- Vol. 7 (1) , 1-16
Characterizing immune variation and diagnostic indicators of preeclampsia by single-cell RNA sequencing and machine learning
Preeclampsia is a multifactorial and heterogeneous complication of pregnancy. Here, we utilize single-cell RNA sequencing to dissect the involvement of circulating immune cells in preeclampsia. Our findings reveal downregulation of immune response in lymphocyte subsets in preeclampsia, such as reduction in natural killer cells and cytotoxic genes expression, and expansion of regulatory T cells. But the activation of naïve T cell and monocyte subsets, as well as increased MHC-II-mediated pathway in antigen-presenting cells were still observed in preeclampsia. Notably, we identified key monocyte subsets in preeclampsia, with significantly increased expression of angiogenesis pathways and pro-inflammatory S100 family genes in VCAN+monocytes and IFN+non-classical monocytes. Furthermore, four cell-type-specific machine-learning models have been developed to identify potential diagnostic indicators of preeclampsia. Collectively, our study demonstrates transcriptomic alternations of circulating immune cells and identifies immune components that could be involved in pathophysiology of preeclampsia.
- 5 January 2024
- Published by Springer Nature in Communications Biology
- Vol. 7 (1) , 1-16
Top Cited PapersOpen AccessCharacterizing immune variation and diagnostic indicators of preeclampsia by single-cell RNA sequencing and machine learning
Preeclampsia is a multifactorial and heterogeneous complication of pregnancy. Here, we utilize single-cell RNA sequencing to dissect the involvement of circulating immune cells in preeclampsia. Our findings reveal downregulation of immune response in lymphocyte subsets in preeclampsia, such as reduction in natural killer cells and cytotoxic genes expression, and expansion of regulatory T cells. But the activation of naïve T cell and monocyte subsets, as well as increased MHC-II-mediated pathway in antigen-presenting cells were still observed in preeclampsia. Notably, we identified key monocyte subsets in preeclampsia, with significantly increased expression of angiogenesis pathways and pro-inflammatory S100 family genes in VCAN+monocytes and IFN+non-classical monocytes. Furthermore, four cell-type-specific machine-learning models have been developed to identify potential diagnostic indicators of preeclampsia. Collectively, our study demonstrates transcriptomic alternations of circulating immune cells and identifies immune components that could be involved in pathophysiology of preeclampsia.
- Open Access
- 7 March 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (5)
Third‐Trimester Maternal Serum Chemerin and Hypertension After Preeclampsia: A Prospective Cohort Study
Background: Limited data are available for postpartum hypertension prediction after preeclampsia. Methods and Results: We examined the association between maternal serum chemerin levels in patients with preeclampsia and blood pressure (BP) levels after delivery in a prospective birth cohort of 15 041 singleton pregnant women. A total of 310 cases among 322 patients with preeclampsia (follow‐up rate, 96.3%) were followed up during a mean 2.8 years after delivery. Compared with matched uncomplicated controls (n=310), serum chemerin measured at ≈35 gestational weeks was significantly increased in preeclampsia (171.8±49.2 versus 140.2±53.5 ng/mL; P P P =0.002). The decision curve analysis revealed a net benefit of the chemerin‐based prediction model for postpartum BP ≥130/80 mm Hg. Conclusions: This study provides the first evidence supporting the independent predictive role of third‐trimester maternal chemerin levels for postpartum hypertension after preeclampsia. Future study is warranted for external validation of this finding.
- 7 March 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (5)
Open AccessThird‐Trimester Maternal Serum Chemerin and Hypertension After Preeclampsia: A Prospective Cohort Study
Background: Limited data are available for postpartum hypertension prediction after preeclampsia. Methods and Results: We examined the association between maternal serum chemerin levels in patients with preeclampsia and blood pressure (BP) levels after delivery in a prospective birth cohort of 15 041 singleton pregnant women. A total of 310 cases among 322 patients with preeclampsia (follow‐up rate, 96.3%) were followed up during a mean 2.8 years after delivery. Compared with matched uncomplicated controls (n=310), serum chemerin measured at ≈35 gestational weeks was significantly increased in preeclampsia (171.8±49.2 versus 140.2±53.5 ng/mL; P P P =0.002). The decision curve analysis revealed a net benefit of the chemerin‐based prediction model for postpartum BP ≥130/80 mm Hg. Conclusions: This study provides the first evidence supporting the independent predictive role of third‐trimester maternal chemerin levels for postpartum hypertension after preeclampsia. Future study is warranted for external validation of this finding.